- All Journals
- Al-Qadisiyah University
- Basrah University
- Kirkuk University
- Mosul University
- The Iraqi Borad for Medical Specialization
- University of Anbar
- University of Technology
- Al Mustafa University
- Al-Zahraa University for Women
- Alnoor University
- Kunooz University
- Misan University
- Ninevah University
- Tikrit University
- University of Al-Hamdaniya
- University of Kerbala
Expression of Mismatch Repair Proteins in Triple Negative Breast Carcinoma Patients and its Correlation with the Clinicopathological Parameters | ||
| Al- Anbar Medical Journal | ||
| Volume 22, Issue 2, April 2026, Pages 101-106 PDF (5.02 M) | ||
| Document Type: Original articles | ||
| DOI: 10.33091/amj.2026.167386.2528 | ||
| Authors | ||
| Heba Adel Al-Saffar* ; Kifah H. Abdul Ghafour | ||
| Department of Pathology and Forensic Medicine, College of Medicine, University of Baghdad, Baghdad, Iraq. | ||
| Abstract | ||
| Background: Triple negative breast carcinoma (TNBC) is an aggressive disease, with a lack of response to targeted therapies, leaving a limited list of effective treatments, including chemotherapy and radiotherapy. Recent studies have shown that certain types of TNBC are immunogenic tumors, that may be suitable targets for immunotherapies. On the other hand, mismatch repair (MMR) expression status is considered an effective biomarker for assessing susceptibility to immunotherapies in multiple solid tumors. Objectives: To assess the expression status of the MMR proteins and their correlation with the clinicopathological parameters in TNBC patients. Materials and Methods: Fifty-three formalin-fixed paraffin-embedded histopathological blocks of diagnosed triple negative invasive ductal breast carcinoma cases were retrieved from the archives department of the histopathological laboratories in Medical City campus hospitals. These blocks were sectioned and stained with monoclonal antibodies, targeting four MMR proteins (MSH2, MSH6, MLH1, and PMS2) to assess the expression status of these proteins in the tumor cells. Results: Of 53 cases, there were 10 (18.9%) deficient in the expression of one or more of the MMR proteins, the MSH2 protein was the least frequently missed protein (n = 3, 5.7%). While PMS2 was the most frequently missed one (n = 10, 18.9%). An insignificant correlation (P-value > 0.05) was found between MMR status and the clinicopathological parameters except for age (P-value < 0.05). Conclusion: Deficient expression status of the MMR proteins was common and showed an insignificant relation with the clinicopathological parameters. | ||
| Keywords | ||
| Breast carcinoma; Mismatch repair proteins; Triple negative breast carcinoma | ||
| References | ||
|
[1] F. M. Hassan, "Risk Factors Associated with Breast Cancer among Women in Iraq: A Case-Control Study," Asian Pacific Journal of Cancer Prevention, vol. 26, no. 5, pp. 1701-1708, 2025.
[2] F. K. Al-Thoubaity, "Molecular classification of breast cancer: A retrospective cohort study," Annals of medicine and surgery, vol. 49, pp. 44-48, 2020.
[3] K.-A. Won and C. Spruck, "Triple-negative breast cancer therapy: Current and future perspectives," International journal of oncology, vol. 57, no. 6, pp. 1245-1261, 2020.
[4] O. Stanowska et al., "PD-L1-Positive high-grade triple-negative breast cancer patients respond better to standard neoadjuvant treatment—a retrospective study of PD-L1 expression in relation to different clinicopathological parameters," Journal of clinical medicine, vol. 11, no. 19, p. 5524, 2022.
[5] L. Chen, H. Zhou, H. Wu, Q. Lu, J. Huang, and S. Wang, "Effect of immunotherapy or anti-angiogenesis therapy combined with chemotherapy for advanced triple-negative breast cancer: A real-world retrospective study," International Immunopharmacology, vol. 143, p. 113516, 2024.
[6] M. Kossai, N. Radosevic-Robin, and F. Penault-Llorca, "Refining patient selection for breast cancer immunotherapy: beyond PD-L1," ESMO open, vol. 6, no. 5, p. 100257, 2021.
[7] T. E. Keenan and S. M. Tolaney, "Role of immunotherapy in triple-negative breast cancer," Journal of the National Comprehensive Cancer Network, vol. 18, no. 4, pp. 479-489, 2020.
[8] F. Shi et al., "Improvement strategy for immune checkpoint blockade: A focus on the combination with immunogenic cell death inducers," Cancer Letters, vol. 562, p. 216167, 2023.
[9] N. Singh, R. Wong, N. Tchrakian, S.-G. Allen, B. Clarke, and C. B. Gilks, "Interpretation and reporting terminology for mismatch repair protein immunohistochemistry in endometrial cancer," The British Association of Gynaecological Pathologists, 2020. https://www.thebagp.org/wp-content/uploads/download-manager-files/1593411202wpdm_BAGP%20MMR%20IHC%20Interpretation%20June%202020.pdf
[10] A. S. Cheng et al., "Mismatch repair protein loss in breast cancer: clinicopathological associations in a large British Columbia cohort," Breast cancer research and treatment, vol. 179, no. 1, pp. 3-10, 2020.
[11] S. Schöniger and J. Rüschoff, "Mismatch repair deficiency and microsatellite instability," Encyclopedia, vol. 2, no. 3, pp. 1559-1576, 2022.
[12] M. M. Kozonoe et al., "Mismatch repair deficiency in bilateral breast cancer," Surgical and Experimental Pathology, vol. 7, no. 1, p. 13, 2024.
[13] A. J. McCarthy et al., "Heterogenous loss of mismatch repair (MMR) protein expression: a challenge for immunohistochemical interpretation and microsatellite instability (MSI) evaluation," The Journal of Pathology: Clinical Research, vol. 5, no. 2, pp. 115-129, 2019.
[14] X.-y. Ren et al., "Mismatch repair deficiency and microsatellite instability in triple-negative breast cancer: a retrospective study of 440 patients," Frontiers in Oncology, vol. 11, p. 570623, 2021.
[15] B. Maraqa et al., "Mismatch repair protein deficiency in triple-negative breast carcinomas," Journal of International Medical Research, vol. 52, no. 6, p. 03000605241259747, 2024.
[16] N. Fusco et al., "Mismatch repair protein loss as a prognostic and predictive biomarker in breast cancers regardless of microsatellite instability," JNCI Cancer Spectrum, vol. 2, no. 4, p. pky056, 2018.
[17] D. Özcan, J. Lade-Keller, and T. Tramm, "Can evaluation of mismatch repair defect and TILs increase the number of triple-negative breast cancer patients eligible for immunotherapy?," Pathology-Research and Practice, vol. 226, p. 153606, 2021.
[18] R. Rammal et al., "Immunohistochemical profile of triple-negative breast cancers: SOX10 and AR dual negative tumors have worse outcomes," Modern Pathology, vol. 37, no. 7, p. 100517, 2024.
[19] C.-Y. Li, S. Zhang, X.-B. Zhang, P. Wang, G.-F. Hou, and J. Zhang, "Clinicopathological and prognostic characteristics of triple-negative breast cancer (TNBC) in Chinese patients: a retrospective study," Asian Pacific journal of cancer prevention: APJCP, vol. 14, no. 6, pp. 3779-3784, 2013.
[20] F. M. Troschel et al., "Knockdown of Musashi RNA binding proteins decreases radioresistance but enhances cell motility and invasion in triple-negative breast cancer," International journal of molecular sciences, vol. 21, no. 6, p. 2169, 2020.
[21] M. D. Burstein et al., "Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer," Clinical Cancer Research, vol. 21, no. 7, pp. 1688-1698, 2015. | ||
|
Statistics Article View: 190 PDF Download: 170 |
||